ClinicalTrials.Veeva
Menu

Find clinical trials for Non-Hodgkin Lymphoma in Warszawa, Mazowieckie

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Lymphoma
B-Cell Lymphoma
Diffuse Large B-Cell Lymphoma
Leukemia
Lymphoid Leukemia
B-Cell Chronic Lymphocytic Leukemia
Cancer

Non-Hodgkin Lymphoma trials near Warszawa, Mazowieckie, POL:

MEN1703 (SEL24) to Treat Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma (JASPIS-01)

The goal of the study is to assess the safety and anti-lymphoma activity of MEN1703 when given as a single-agent or combined with glofitamab-...

Enrolling
Non-Hodgkin Lymphoma, B-cell
Drug: Glofitamab
Drug: MEN1703

Phase 2

Ryvu Therapeutics

Warsaw, Poland and 8 other locations

This is a Phase I/II, multicenter, open-label, dose-escalation study designed to evaluate the efficacy, safety, tolerability and pharmacokinetics (PK...

Enrolling
Non-Hodgkin's Lymphoma
Drug: Glofitamab
Drug: Obinutuzumab

Phase 1, Phase 2

Roche
Roche

Warszawa, Poland and 40 other locations

This study is researching an investigational drug, odronextamab, in adult patients B-cell non-Hodgkin's lymphoma (B-NHL).T...

Enrolling
B-cell Non-Hodgkin Lymphoma (B-NHL)
Drug: Odronextamab

Phase 2

Regeneron Pharmaceuticals
Regeneron Pharmaceuticals

Warszawa, Poland and 137 other locations

This is an open-label, multi-center Phase 1/2 study of oral LOXO-305 (pirtobrutinib) in patients with CLL/SLL and NHL who have failed or are intolera...

Active, not recruiting
Marginal Zone Lymphoma
Small Lymphocytic Lymphoma
Drug: Venetoclax
Drug: Rituximab

Phase 1, Phase 2

Loxo Oncology
Loxo Oncology

Warszawa, Poland and 55 other locations

The purpose of this extension study is to provide venetoclax and obtain long-term safety data for subjects who continue to tolerate and derive benefi...

Active, not recruiting
Non-Hodgkin's Lymphoma
Multiple Myeloma
Drug: Venetoclax

Phase 3

AbbVie
AbbVie

Warszawa, Mazowieckie, Poland and 55 other locations

This study evaluates the addition of nivolumab to gemcitabine, oxaliplatin plus rituximab in case of B-cell lymphoma...

Active, not recruiting
Lymphoma, Non-Hodgkin
Device: Oxaliplatin
Drug: Rituximab

Phase 2, Phase 3

Universität des Saarlandes

Warsaw, Poland and 76 other locations

The primary purpose of the study is to assess safety, and to identify the recommended phase 2 dose (RP2D) of tolinapant in combination with oral deci...

Active, not recruiting
Relapsed/Refractory Peripheral T-cell Lymphoma
Drug: Decitabine + Cedazuridine
Drug: Tolinapant

Phase 1, Phase 2

Taiho Pharma
Taiho Pharma

Warsaw, Masovia, Poland and 45 other locations

This study will provide continuing availability to tazemetostat for people that have previously completed participation in a tazemetostat study, eith...

Invitation-only
Non-Hodgkin Lymphoma (NHL)
Follicular Lymphoma (FL)
Drug: Tazemetostat

Phase 1, Phase 2

Epizyme

Warszawa, Poland and 28 other locations

in combination with bendamustine and rituximab (BR) compared with placebo plus BR in subjects with previously untreated mantle cell lymphoma....

Active, not recruiting
Lymphoma, Mantle Cell
Drug: Bendamustine
Drug: Acalabrutinib

Phase 3

Acerta Pharma
Acerta Pharma

Warszawa, Poland and 227 other locations

is focused on patients who have relapse/refractory aggressive B-cell lymphoma. The aim of the study is to see how safe and tolerable the stu...

Enrolling
Relapsed/Refractory Aggressive B-Cell Lymphoma
Drug: cemiplimab
Drug: odronextamab

Phase 1

Regeneron Pharmaceuticals
Regeneron Pharmaceuticals

Warszawa, Poland and 34 other locations

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems